This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Zeller, W. J. Articles by Schmähl, D. Search for Related Content PubMed PubMed Citation Articles by Zeller, W. J. Articles by Schmähl, D.

Chemotherapy of the Transplantable Acute Leukemia L5222 in Rats

Institute of Toxicology and Chemotherapy, German Cancer Research Center, Kirschnerstrasse 6, Postfach 449, D 6900 Heidelberg I. Germany

This study presents results of single-drug and combination chemotherapy of the transplantable acute leukemia L5222 in BD IX rats.

In leukemia L5222 there is a direct relationship between the number of transplanted cells and mean life expectancy.

After single-drug therapy with L-asparaginase, 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), cyclophosphamide, cytosine arabinoside, daunomycin, 6-mercaptopurine, methylglyoxal bis(guanylhydrazone) dihydrochloride, prednisolone, or vincristine, the best therapeutic effect was observed with BCNU and cyclophosphamide. A massive-dose therapy with BCNU repeated twice or a combination of vincristine with cyclophosphamide or BCNU with cyclophosphamide yielded a high percentage of cures.

Moreover, leukemia L5222 seems to be suitable for studying the influence of drugs on the proliferation kinetics of leukemia cells.

Received 6/ 3/74. Accepted 1/ 2/75.